slv-306 and Hypertension

slv-306 has been researched along with Hypertension* in 2 studies

Reviews

2 review(s) available for slv-306 and Hypertension

Article	Year
[Physiological and pathophysiological roles of the endothelin converting enzymes]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 9 Topics: Animals; Aspartic Acid Endopeptidases; Benzazepines; Benzofurans; Drug Design; Endothelin-Converting Enzymes; Glycopeptides; Heart Failure; Humans; Hypertension; Metalloendopeptidases; Mice; Mice, Knockout; Myocardial Infarction; Organophosphonates; Phenylalanine; Tetracyclines; Tetrazoles	2004
SLV-306. Solvay. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:3 SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the potential treatment of essential hypertension and congestive heart failure. The compound is currently undergoing phase II clinical trials in Belgium. Topics: Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Benzazepines; Clinical Trials as Topic; Endothelin-Converting Enzymes; Humans; Hypertension; Metalloendopeptidases; Neprilysin	2003

Article

Year

[Physiological and pathophysiological roles of the endothelin converting enzymes].

Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 9

Topics: Animals; Aspartic Acid Endopeptidases; Benzazepines; Benzofurans; Drug Design; Endothelin-Converting Enzymes; Glycopeptides; Heart Failure; Humans; Hypertension; Metalloendopeptidases; Mice; Mice, Knockout; Myocardial Infarction; Organophosphonates; Phenylalanine; Tetracyclines; Tetrazoles

2004

SLV-306. Solvay.

Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:3

SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the potential treatment of essential hypertension and congestive heart failure. The compound is currently undergoing phase II clinical trials in Belgium.

Topics: Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Benzazepines; Clinical Trials as Topic; Endothelin-Converting Enzymes; Humans; Hypertension; Metalloendopeptidases; Neprilysin

2003